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Abstract 
The report summarizes the Second International Workshop of Cancer Systems Biology held on July 5-6, 
2012 in Changchun, China. The goal of the workshop was to bring together cancer researchers with different 
backgrounds to share their views about cancer and their experiences in fighting against cancer, and to gain 
new and systems鄄  level understanding about cancer formation, progression, diagnosis, and treatment through 
exchanging ideas. 
Conference Report 
The Second International Workshop of Cancer 
Systems Biology (ICSB) (http://ccst.jlu.edu.cn/icsb2012/), 
hosted by Jilin University, was held from July 5 to 6, 
2012 in Changchun, China. During this two­day meeting, 
21 invited speakers, 7 from China, 13 from the United 
States, and 1 from Canada, gave speeches covering a 
wide range of topics on cancer systems biology to an 
audience of approximately 300 people from across 
China. The 21 talks roughly fell into four categories: 
cancer genome analysis and information discovery, 
cancer mechanism studies, biomarker discovery, and 
cancer treatment strategies. By design, these talks were 
delivered by cancer researchers and practitioners with 
diverse backgrounds who may not otherwise have 
opportunities to meet and share their visions about 
cancer studies in an open and scientifically stimulating 
environment. Among the speakers were cancer 
biologists who study specific cancer pathways, 
computational cancer biologists who rely on large­scale 
data for global information discovery, computational 
modelers who examine dynamic properties of cancer, 
immunologists who study cancer in a larger context than 
just tumors, and clinicians who use different strategies 
and techniques to treat cancer patients. Having such a 
diverse group of people speaking to each other and to 
an audience with an even wider range of expertise 
generated much excitement. At the end of the meeting, 
virtually all speakers and many attendees expressed 
praise for the workshop as one of the best they had 
attended, having been impressed by the overall quality of 
the talks and the intellectual level of the dialog it created. 
This meeting, which is the second in its series, was 
initiated by Professor Ying Xu (University of Georgia and 
Jilin University) and Professor Yan­Chun Liang (Jilin 
University) in early 2011. The overall consideration in 
organizing this annual meeting is to bring together 
cancer researchers with different backgrounds to share 
their views and experiences in fighting cancer and to 
gain new systems­level understanding of cancer 
formation, progression, diagnosis, and treatment through 
exchanging ideas. Professor Liang Hu, Dean of the 
College of Computer Science and Technology at Jilin 
University, generously agreed to financially sponsor the 
first three annual meetings of this series, which has 
made this and the previous meeting possible. Like in the 
first meeting in 2011, the organizers felt very fortunate 
for the opportunity to bring together this group of leaders 
in their respective research areas to present their 
science and lead discussions. 
Cancer Genome/Epigenome Sequencing 
and Information Discovery 
To understand the genetic basis of cancer, two large 
cancer genome sequencing projects have been initiated: 
one by the International Cancer Genome Consortium 
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and the other by the US National Cancer Institute and 
National Human Genome Research Institute, named The 
Cancer Genome Atlas (TCGA). TCGA aims to develop a 
complete 野atlas冶 of all genomic alterations involved in 
dozens of major cancer types. Dr. Wei Zhang (MD 
Anderson Cancer Center), a principal investigator of the 
TCGA Initiative, presented a study by his group on the 
implications of  and  mutations on ovarian 
cancer prognosis. They found that  ­mutated 
ovarian cancers have higher levels of gene mutations, 
respond better to front­line therapy, and have a longer 
overall and progression­free survival. In addition, he also 
discussed their recent genome sequencing study of 
colorectal cancer, which was published in the July 2012 
issue of  , as well  as their bioinformatic analyses 
on endometrial cancer that revealed three distinct 
subtypes with distinct pathway­ level characteristics. 
Dr. Juan Cui (University of Georgia) introduced her 
group爷s recent study in which the whole genomes of five 
gastric adenocarcinomas and matching controls were 
sequenced. The density of the mutation spectrum of 
each cancer genome ranged from 6.8 to 13.8 mutations 
per Mb of DNA. In total, 407 non­synonymous somatic 
point variations were identified, primarily occurring in 
mucins and transcription factors. Seventy­six genes had 
copy­number changes, and 679 genomic rearrange鄄  
ments were detected. The study revealed that 79.6% of 
the chromosomal rearrangements occurred among 
neighboring regions in the folded chromosomes, based 
on mapping of the boundaries of the rearranged regions 
to the folded three­dimensional structures of the human 
chromosomes and the replication timing profiles. 
In his presentation, Dr. Jin­Tang Dong (Emory 
University) demonstrated how a tumor suppressor gene 
can be identified from a chromosomal region that is 
frequently deleted in human cancer. Specifically, he and 
his colleagues presented krueppel­like factor 5 (KLF5) as 
a tumor suppressor gene based on  and 
studies and reported a novel mechanism for how KLF5 
can be inactivated in human cancer. Interestingly, animal 
studies demonstrated that KLF5 can act as both a tumor 
suppressor and promoter, and biochemical analyses of 
cultured epithelial cells revealed a possible mechanism 
for how KLF5 can switch functions. In their 
studies, Dr. Dong爷s group found that KLF5 is a cofactor 
of TGF­茁 signaling, and TGF­茁  ­induced acetylation of 
KLF5 is the key event that reverses the function of 
KLF5. In the absence of TGF­茁  , KLF5 is not acetylated 
and promotes cell proliferation by regulating cell cycle 
genes. However, when TGF­茁   is present, KLF5 is 
acetylated and the acetylation reassembles the KLF5 
transcriptional complex, leading to a change in gene 
transcription and the reversal of KLF5 function. 
DNA methylation is associated with silencing or 
overexpression of many biologically important genes in 
almost all types of cancer. Dr. Dong Xu (University of 
Missouri) described his group爷s bisulfite­sequencing 
analysis of DNA methylation patterns across different 
cancer tissue samples. They identified digital profiles of 
aberrant DNA methylation and suggested potential 
methylation biomarkers for cancer subtypes. They also 
studied sequence and methylation patterns among DNA 
methyltransferases and found long­range patterns in the 
flanking sequences around methylation sites and 
cooperativity among different DNA methyltransferases. In 
addition, they found that DNA methylation in the 3'­UTR 
was positively correlated with expression of the upstream 
gene, in contrast to negative correlation of expression 
with its promoter region. Their analysis indicates that 3'­ 
UTRs are hypomethylated in tumor samples and that 
genes with longer 3'­UTRs tend to have more differential 
methylation and thus a higher ability to regulate the gene 
expression. 
In addition, Dr. Wen­Yi Wang (MD Anderson Cancer 
Center) also presented her work on cancer genome 
analyses and applications. 
Mechanisms of Cancer 
Four talks were focused on mechanisms of cancer. 
Speakers discussed the topic from their own unique 
perspectives, some with a more traditional focus on 
specific cancer­related pathways and others with a focus 
on global pictures. 
Dr. Ying Xu (University of Georgia) presented a 
model showing that hypoxia may serve as a key driver 
for cancer growth. The idea of the model is that as a cell 
becomes increasingly more hypoxic, there is a switch in 
cellular respiration from oxidative phosphorylation to 
glycolysis, which was first reported 90 years ago by Otto 
Warburg. Such a switch in energy metabolisms leads to 
decreased generation of ATP per glucose and results in 
increased glucose uptake by the affected cells, a 
phenomenon that is widely observed through cancer 
imaging data. The increased accumulation of glucose is 
due to the fact that the outgoing rates of carbons through 
lactate and the electron transport chain are significantly 
lower than incoming rates of carbons from the glucose. 
The accumulated glucose/intermediates must be cleared 
or cells will die. Cells have evolved to adopt the process 
of biosynthesis to relieve this carbon burden, which 
gradually leads to systematic changes in cellular 
metabolism and ultimately results in the synthesis of new 
cells. This cycle accelerates as the cell population 
becomes increasingly more hypoxic and forms a 
self­propelling cycle driven by the force to remove 
excess carbons. This model is consistent with the large­ 
scale transcriptomic data. 
Systems biology in cancer research 
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Evasion of apoptosis is one of the key hallmarks of 
cancer and a major target of cancer therapy. Dr. 
Shi­Yong Sun (Emory University) discussed death 
receptor 5 (DR5), a cell surface pro­apoptotic death 
receptor for tumor necrosis factor­related apoptosis­ 
inducing ligand (TRAIL). Oncogenic mutations of Ras 
and B­Raf frequently occur in cancer and are critical to 
cell transformation and tumorigenesis. In their recent 
study, Dr. Sun and colleagues forced expression of 
oncogenic Ras or B­Raf  and demonstrated that 
these proteins positively regulate DR5 expression. This 
finding is further supported by results showing that 
knockdown of endogenous K­Ras or B­Raf reduced the 
expression of DR5. Importantly, they also showed that 
Ras induced DR5 expression through co­activation of the 
ERK/RSK and JNK signaling pathways and subsequent 
cooperative effects among the transcriptional factors 
CHOP, Elk1, and c­Jun. 
In addition, Dr. Zhiren Luis Liu (Georgia State 
University) and Dr. Xiaole Shirley Liu (Harvard University 
and  Dana­Farber Cancer Institute) also presented their 
work. 
Search for Biomarkers for Cancer 
Subtyping, Diagnosis, and Prognosis 
There were six talks on the identification and 
application of biomarkers. Dr. Ya­Ping Tian (Beijing 301 
Hospital) described his group爷s study of the peripheral 
blood from which they identified an 8­gene panel that 
could be used to distinguish blood samples of hepatitis 
B, liver cirrhosis, and hepatocellular carcinoma patients 
from those of healthy donors with high statistical 
significance. Based on this study, they have developed a 
peripheral blood gene expression profiling test (GeXP) 
for differential diagnosis of hepatic diseases. 
Dr. Chao­Nan (Miles) Qian (Van Andel Research 
Institute and Sun Yat­sen University Cancer Center) 
presented his team爷s finding that the secreted molecules 
serglycin and interleukin­8 (IL­8) promote metastasis of 
nasopharyngeal carcinoma (NPC) cells through autocrine 
and paracrine mechanisms and serve as independent 
prognostic factors for the survival of NPC patients. They 
found that IL­8 can induce the expression of many 
mesenchymal markers and suppress the expression of 
epithelial markers. Clinically, cancer cells with a high 
propensity for metastasis are the primary cause of 
patient death. However, these cells may be present in 
very low numbers in primary tumors, hence making gene 
expression profiling a major challenge. Therefore, as Dr. 
Qian爷s group demonstrated through their studies, using 
parental cells to isolate metastatic clones may be a 
useful strategy to overcome this challenge and allow 
identification of the pro­metastatic gene expression 
signature by gene expression profiling. 
Dr. Bing Zhang (Vanderbilt University) discussed his 
group爷s work on identifying prognostic markers for 
colorectal cancer. They investigated eight published 
colorectal cancer gene expression signatures. Using a 
random walk­based approach, they integrated these 
signatures and publicly available somatic mutation data 
on a protein­protein interaction network and inferred 487 
genes as plausible candidate molecular underpinnings 
for the colorectal cancer recurrence phenotype. The 
resultant list of genes was deemed an NEM signature. 
An NEM signature­based survival support vector 
machine prognostic model was trained using a gene 
expression dataset and tested on an independent 
dataset. The model­based scores were 75.7% 
concordant with patient survival data and separated 
patients into two groups with significantly different 
relapse­free survival (  = 0.002). Furthermore, adjuvant 
chemotherapy was significantly associated with 
prolonged survival of the high­risk patients (  = 0.006) 
but not beneficial to the low­risk patients (  = 0.491). 
Thus, the NEM signature not only reflects colorectal 
cancer biology but also informs patient prognosis and 
treatment response. 
The other biomarker talks were focused on existing 
techniques for biomarker identification. For example, one 
major problem is that most biomarkers cannot be 
reproducibly identified by independent studies. To 
address this, Dr. Zheng Guo (Harbin Medical University) 
proposed a new strategy of using scores to evaluate the 
functional reproducibility of cancer biomarkers based on 
molecular models that take into account the functional 
associations among the marker genes/proteins. The 
biological assumption underlying a score is statistically 
testable to explain the diverse but functionally related 
biomarker genes/proteins. Dr. Guo reported that 
biomarkers identified using this method could be 
reproducibly detected when using different omic 
datasets. 
Another serious issue is that while both molecular 
and network biomarkers can be used to distinguish 
disease samples from normal samples, neither are 
guaranteed to successfully identify pre­disease samples 
due to their static nature. Thus, these markers are not 
useful for early diagnosis. In a departure from traditional 
approaches, Dr. Luo­Nan Chen (Chinese Academy of 
Sciences, Shanghai) has recently developed a new 
theory of dynamical network biomarkers (DNBs) based 
on nonlinear dynamical theory and network theory. 
Applying this theory, Dr. Chen and his research team 
showed for the first time that DNBs can distinguish the 
pre­disease state from the normal state, even with small 
numbers of samples, and therefore have a great 
potential to achieve 野real冶 early diagnosis of complex 
diseases like cancer. 
Juan Cui et al. Systems biology in cancer research 
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Dr. Edwin Wang (National Research Council Canada 
and McGill University) showed that alterations of tumor 
suppressor genes are essential to cancer development 
and progression. Mutation of tumor suppressor genes 
often increases genomic instability, which makes 
passenger, or non­specific, signals more common in 
tumor cells than in other cell types and causes variability 
in the gene expression profiles between individual 
tumors. Thus, the 野real冶 cancer gene expression signals 
may be buried in these highly varied profiles. These 
insights prompted Dr. Wang and colleagues to develop a 
new algorithm that focuses on functional modules 
instead of network modules, which are limited by a lack 
of comprehensive network data. These functional 
modules provide several advantages as they (1) reduce 
potential passenger signals; (2) overcome the well­ 
known over­fitting problems; and (3) make the effects of 
the biomarkers more stable due to the functional 
interactions between the genes in a  functional module. 
As proof­of­concept, they successfully  applied the 
algorithm and identified breast cancer prognostic 
biomarkers that could identify low­risk patient  in eight 
independent cohorts containing more than 1300 patients. 
Dr. Shyr Yu (Vanderbilt University) also presented a 
talk about issues with the existing methods commonly 
used in bioinformatics studies and offered new solutions. 
Drug Targets and Cancer Treatment 
Strategies 
In his talk, Dr. Wei­Ping Zou (University of 
Michigan) focused on Th17 cells in the tumor 
microenvironment. Th17 cells phenotypically resemble to 
terminally differentiated memory T cells, but are different 
from central memory, exhausted and senescent T cells. 
His group demonstrated that Th17 cells mediate and 
promote long­term antitumor immunity. Furthermore, 
Th17 cells have stem cell­like features including high 
capacity of proliferative self­renewal, potent persistence 
and apoptotic resistance  , and the generation of 
other types of T helper cells. Moreover, the stem cell­like 
characteristics of these cells are regulated by the 
signaling pathways of hypoxia­inducible factor 1琢 (HIF1琢  ) 
and Notch. Thus, Th17 cells may be a long­lived 
proliferating T cell population with stem cell charac鄄  
teristics, which may be important determinants in Th17 
biology. Therefore targeting the Th17 stemness would be 
therapeutically meaningful for treating patients with 
chronic diseases affected by Th17 cells 
Electroporation is becoming a powerful and yet very 
simple drug delivery tool for cancer treatment. 
Administration of DNA encoding IL­12 has not only 
eradicated the directly injected melanoma tumors but 
also caused regression of collateral melanoma tumors in 
2 out of 19 patients with in­transit melanoma in a phase I 
trial by Adil Daud. Dr. Shu­Lin Li (MD Anderson Cancer 
Center) reported that he and his colleagues generated a 
tumor­targeted IL­12 that is more effective than wild­type 
IL­12 in inhibiting metastatic tumors. He also showed 
results of their study in which the IL­12 gene and 
chemical medicine were co­administered via 
electroporation to treat recurrent and large­volume 
squamous cell carcinoma in dogs. The central hypo鄄  
thesis behind this co­administration approach is that 
chemotherapy delivered by electroporation will cause 
tumor cell death and release of tumor antigens, while 
IL­12 gene therapy delivered by electroporation will 
recruit and stimulate immune cells to process the 
released antigens to generate an antitumor immune 
memory. The success in causing tumor regression in 
dogs provides solid evidence to support this hypothesis. 
Dr. Ya­Jun Guo, Dr. Xiao­Ning Wang, and Dr. Ying 
Gu, all from Beijing 301 Hospital, also presented their 
experience in treating cancers using different techniques 
and strategies. 
Concluding Remarks 
Forty years have passed since the declaration of 
the 野war on cancer冶 in the early 1970s. While 
considerable progress has been made in our overall 
ability to fight this disease, cancer remains the second 
leading cause of death worldwide. The reality is that we 
are still far from reaching the goal set 40 years ago. The 
general consensus in the field has been that 
fundamentally new ways to study cancer should be 
developed based on the lessons learned in the past. We 
aimed to use this meeting series to bring together 
researchers who have been studying cancer from very 
different perspectives to develop novel views, ask deeper 
questions about the essence of cancer, and generate 
new dialogs/collaborations leading to fundamentally new 
understanding about cancer at the systems level. 
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